US FDA approves Jazz Pharmaceuticals’ Modeyso to treat recurrent H3 K27M-mutant diffuse midline glioma: Dublin Friday, August 8, 2025, 11:00 Hrs [IST] Jazz Pharmaceuticals plc, ...

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of diffuse midline glioma harboring an ...

Central Valley Snowie, a family-owned business in Modesto, is asking for community help after a hit-and-run destroyed their ...

When Jazz Pharmaceuticals' incoming CEO Renee Gala takes the reins at the drugmaker next week, she'll have a brand-new launch ...

The US Food and Drug Administration (FDA) has given accelerated approval to Jazz Pharmaceuticals for Modeyso (dordaviprone) ...

The U.S. FDA granted accelerated approval to Modeyso for the patients with diffuse midline glioma with an H3 K27M mutation ...

The FDA has granted accelerated approval to Modeyso (dordaviprone) for the treatment of certain patients with diffuse midline glioma.